



Centre for
Heart Lung Innovation
UBC and St. Paul's Hospital

Centre for Heart Lung Innovation Research in Progress (R.I.P.)



Early endothelial function activation by angiotensin II receptor blockers mitigates vascular damage in diabetes

Christopher Yuen
PhD Student
Dr. Pascal Bernatchez

Monday Oct 23rd, 2023
9:00 – 10:00 a.m.

James Hogg Conference Centre (JHCC) RM 103
Zoom Video Conference
(Meeting ID: 693 1997 7044; Passcode: 030679)

“Long-term cardiovascular complications are one of the main concerns of children living with type 1 diabetes (T1D). After immune cells attack the pancreatic beta cells, insulin production is low causing hyperglycemia which affects vascular homeostasis.

Traditionally, cardiovascular complications were thought to occur several years post diagnosis, however recent studies report early vascular damage in children with T1D.

Our lab has shown that angiotensin II receptor blockers (ARBs) have highly effective, unique protective endothelial function activating properties in a pleotropic blood pressure independent fashion. This suggests that pleotropic ARBs may be far superior to other antihypertensives for preventing or reversing vascular dysfunction in diabetes. However, whether early intervention with ARBs can prevent the development of chronic vascular damage such as arterial stiffness and vascular remodeling in diabetes remains unknown.”

This event is a Self-Approved Group Learning Activity as defined by the Maintenance Certification Program of the Royal College of Physicians and Surgeons of Canada



a place of mind

THE  LUNG ASSOCIATION™
British Columbia



HEART &
STROKE
FOUNDATION
OF BC & YUKON

Finding answers. For life.